AI Article Synopsis

  • There are currently no suitable hydrocortisone formulations for treating children with congenital adrenal hyperplasia (CAH) that allow for precise, smaller dosing adjustments.*
  • Physicians often have to improvise with existing 5-mg tablets, leading to potential dosing errors, as seen in a case of a young girl who developed iatrogenic Cushing syndrome.*
  • Switching to a specially compounded hydrocortisone suspension improved her symptoms and growth, underscoring the necessity for commercially available pediatric formulations.*

Article Abstract

Currently there are no commercially available hydrocortisone formulations for the treatment of children with congenital adrenal hyperplasia (CAH) that allow for smaller doses (0.1-1.25 mg) and incremental adjustments needed to control excess androgen production and avoid the negative effects of overtreatment. This lack of availability has led physicians to recommend dividing hydrocortisone 5-mg tablets into 4 to 6 pieces, compounding capsules or hydrocortisone suspension, or crushing 5- or 10-mg tablets in 5 or 10 mL of water. We report a case of iatrogenic Cushing syndrome in a 6-year 11-month-old girl with salt-wasting CAH treated with hydrocortisone tablets that were administered after crushing and dispersing into water to obtain the prescribed dose. She presented with poor growth, increasing body mass index (BMI), excess downy hair, round facies, and gastric ulcers. Her hydrocortisone dose was 8.1 mg/m/day. Results for all adrenal steroid concentrations were undetectable at 8 am, 12 hours after her last dose. The year prior to presentation her parents began dissolving 10 mg of hydrocortisone in 10 mL of water and using this preparation over the course of 24 hours, which coincided with rapid increase of BMI. We switched her to a pharmacy-compounded alcohol-free hydrocortisone suspension with total daily doses ranging from 6.5 to 8.2 mg/m/day, which resulted in resolution of her cushingoid features, a decrease in BMI, and catch-up growth. Our case highlights that manipulation of hydrocortisone tablets by parents can result in great variability in dosing and the need for commercially available pediatric formulations allowing for smaller dosing required in young children.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417883PMC
http://dx.doi.org/10.1210/jendso/bvaa091DOI Listing

Publication Analysis

Top Keywords

hydrocortisone tablets
12
manipulation hydrocortisone
8
iatrogenic cushing
8
cushing syndrome
8
hydrocortisone
8
hydrocortisone suspension
8
tablets
5
tablets leads
4
leads iatrogenic
4
syndrome 6-year-old
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!